Radient Pharmaceuticals Corporation fka RXPC

[lakeshore555]

Old, whether or not UNI keeps paying the license fee and/or pursues the patent matters little.

There's not much of a market for DR-70 and the horseradish ingredient is in short supply with no known substitute. It's very unlikely that anyone will make a generic DR-70 after the patent expires.

DR-70 is just another example of a device that got FDA clearance but failed on the market. There's more money to be made trading stocks of companies that don't have FDA clearance or approval yet, IMO.

Biotech is all about hype. This company has nothing left to hype, I think.